Newstep

NewStep Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies for cancer and autoimmune diseases. Headquartered in Suzhou, China, the company leverages its proprietary antibody engineering platforms to create a pipeline of monoclonal and multi-specific antibodies. Its lead program, NST-002, is a humanized monoclonal antibody targeting Signal regulatory protein alpha (SIRPα), which aims to block the 'don't eat me' signal in the CD47-SIRPα pathway to promote macrophage-mediated tumor cell clearance. NewStep's R&D strategy focuses on targeting both innate and adaptive immune checkpoints to overcome resistance to current therapies. The company is backed by prominent venture capital firms and maintains clinical operations in China, Australia, and the United States.